Figure 4.

Effect of i.pl. treatment with selective kinin B₁ or B₂ receptor antagonists, DALBK (3 nmol per paw, i.pl.) and Hoe 140 (3 nmol per paw, i.pl.), respectively, on paclitaxel-induced mechanical hyperalgesia in CD1 mice. A single injection of the drugs was given 7 (A) and 14 (B) days after the first paclitaxel (PTX) injection. (C) Effect of the i.pl. injection of kinin B₁ or B₂ receptor agonists, DABK (20 nmol per paw, i.pl.) and BK (10 nmol per paw, i.pl.), respectively, on licking behaviour in vehicle- and paclitaxel-treated CD1 mice. Each group represents the mean of five to six animals, and the error bars indicate the SEM. (A, B) *P < 0.05, significantly different from paclitaxel-treated mice (two-way anova followed by Bonferroni post-test). BL, baseline withdrawal threshold. (C) *P < 0.05, significantly different from saline- (i.pl.) injected mice (one-way anova followed by the Newman–Keuls post-test).